Eleanor Health Secures $20M for Value-Based Addiction and Mental Health Treatment
What You Should Know:
– Eleanor Health, a Waltham, MA-based outpatient addiction and mental health provider delivering convenient and comprehensive care through a population and value-based payment structure, today announced it has closed an oversubscribed $20M Series B financing. The round included participation from all existing investors including Town Hall Ventures, Echo Health Ventures, and Mosaic Health Solutions, as well as new participation from Warburg Pincus.
– Committed to health and wellbeing without judgment, Eleanor Health is focused on delivering whole-person, comprehensive care to transform the quality, delivery, and accessibility of care for people affected by addiction.
Posted on 309
Strive Health has selected Colorado for its long-term headquarters expansion. The Denver-based startup has grown its employee base by more than 600% in the last year and today’s announcement includes the addition of 250 new Colorado jobs that support the company’s expansion in roles that include clinical, technical, data management, operations, and strategy.
“As we kick off National Economic Development Week, it is fitting that we announce the continued growth and expansion of a Denver-based startup right here in Colorado,” said Governor Jared Polis.
“These high-quality jobs are a great benefit to Colorado as Strive Health continues to solidify Colorado’s reputation for healthcare and health tech innovation.”
Aetion Closes $110M Series C Funding Round Led by Warburg Pincus
Financing will advance Aetion s technology, accelerate global growth, and drive expansion in new verticals, further cementing Aetion s leadership position in real-world evidence
News provided by
Share this article
BOSTON and NEW YORK, May 11, 2021 /PRNewswire/ Health care technology company
Aetion announced today a $110 million Series C fundraise, led by Warburg Pincus, a leading global growth equity firm, with additional investments from B Capital and Foresite Capital. Aetion s existing backers New Enterprise Associates (NEA) and Flare Capital Partners also joined the round. Aetion has raised a total of $212 million to date. The capital infusion supports Aetion s continued growth and industry leadership in the real-world evidence (RWE) space. In the last year alone, Aetion nearly doubled revenue and secured 100 percent of customer renewals while establishing valuable industry collaborations. Aetion became the f
Accountable-care organizations call for delay in new reporting requirements
Plus:
Bushwick digital pharmacy opens Harlem location
Mother Cabrini awards $20M to nonprofits for Covid efforts
Print
The nation s accountable care organizations sent a letter last week to the Centers for Medicare and Medicaid Services, urging the agency to delay certain changes to quality reporting requirements for value-based payments. Backed by large, national medical groups, the letter warned that rushed implementation of these changes could deter new organizations from joining the shared-savings program or even cause organizations to leave it.
Accountable care organizations are groups of hospitals, physicians and health centers that work to improve health outcomes while reducing cost. Organizations that achieve savings are entitled to share them with CMS, and those that incur losses have to chip in.
ICER to Use Aetion Observational RWE to Update Value Assessment of Treatments for Hereditary Angioedema
- New ICER pilot will incorporate more than 24 months of observational real-world demographic, utilization, and cost data to further clarify therapies value
- Through continued use of the Aetion Evidence Platform®, ICER advances the use of transparent, replicable real-world evidence in health technology assessment
News provided by
Share this article
ICER) today announced it is using observational real-world evidence (RWE) to update its
2018 assessment of three therapies for long-term prophylaxis against hereditary angioedema (HAE) attacks: lanadelumab (Takhzyro®, Takeda), and two C1 esterase inhibitors (Haegarda®, CSL Behring; and Cinryze®, Takeda).